Article
San Francisco - Inamed Corp. received approval from the U.S. Food and Drug Administration to compete against what it considers a formidable foe - its own ZyDerm and ZyPlast products.
Review Compares Psoriasis Therapies in Asian Populations
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Subgroup Analysis Reveals Equal Benefit of Brodalumab in Obese vs Non-Obese Patients With Psoriasis
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Patients Treated for Acne Exhibit Higher Sebum, Hydration, and TEWL Levels than General Population
Exploring the Atopic Dermatitis Treatment Paradigm and Challenging Cases